Codexis Crecimiento futuro

Future controles de criterios 1/6

Codexis se prevé un crecimiento anual de los beneficios y los ingresos de 50.4% y 18.4%, respectivamente, mientras que el BPA aumentará de grow a 51.6%.

Información clave

51.4%

Tasa de crecimiento de los beneficios

52.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	16.1%
Tasa de crecimiento de los ingresos	14.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	28 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

Dec 20

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Feb 27

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Feb 25

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Nov 05

Codexis appoints Kevin Norrett as chief operating officer

Oct 03

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Aug 23

Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Jul 28

Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead

Jul 27

Codexis gets new executive chief

Jul 18

Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?

Jul 06

Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching

May 10

Codexis: A Company Rooting Itself In A Blossoming Market

Apr 18

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Apr 09

Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?

Mar 14

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CDXS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	84	-16	-4	N/A	2
12/31/2025	62	-49	-54	N/A	6
12/31/2024	65	-46	-55	N/A	7
12/31/2023	70	-76	-57	-53	N/A
9/30/2023	74	-82	-41	-37	N/A
6/30/2023	99	-57	-6	-1	N/A
3/31/2023	116	-48	8	13	N/A
12/31/2022	139	-34	3	11	N/A
9/30/2022	133	-31	-7	7	N/A
6/30/2022	135	-19	-29	-13	N/A
3/31/2022	122	-21	-35	-19	N/A
12/31/2021	105	-21	-28	-14	N/A
9/30/2021	101	-15	-26	-16	N/A
6/30/2021	83	-23	-26	-20	N/A
3/31/2021	72	-25	-27	-21	N/A
12/31/2020	69	-24	-20	-16	N/A
9/30/2020	67	-21	-21	-19	N/A
6/30/2020	70	-14	-20	-16	N/A
3/31/2020	68	-14	-15	-11	N/A
12/31/2019	68	-12	-16	-13	N/A
9/30/2019	66	-12	-14	-10	N/A
6/30/2019	61	-14	-12	-10	N/A
3/31/2019	62	-11	-16	-13	N/A
12/31/2018	61	-11	-17	-14	N/A
9/30/2018	66	-9	-8	-6	N/A
6/30/2018	59	-18	-11	-9	N/A
3/31/2018	56	-20	-10	-9	N/A
12/31/2017	50	-23	-10	-9	N/A
9/30/2017	38	-29	N/A	-12	N/A
6/30/2017	43	-18	N/A	-14	N/A
3/31/2017	49	-9	N/A	-6	N/A
12/31/2016	49	-9	N/A	-2	N/A
9/30/2016	50	-5	N/A	0	N/A
6/30/2016	53	-1	N/A	8	N/A
3/31/2016	43	-9	N/A	4	N/A
12/31/2015	42	-8	N/A	0	N/A
9/30/2015	44	-5	N/A	-3	N/A
6/30/2015	34	-15	N/A	-1	N/A
3/31/2015	35	-18	N/A	-1	N/A
12/31/2014	35	-19	N/A	0	N/A
9/30/2014	31	-29	N/A	-9	N/A
6/30/2014	27	-34	N/A	-19	N/A
3/31/2014	28	-38	N/A	-22	N/A
12/31/2013	32	-41	N/A	-23	N/A
9/30/2013	30	-47	N/A	-24	N/A
6/30/2013	53	-40	N/A	-19	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: CDXS se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: CDXS se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: CDXS se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: CDXSSe prevé que los ingresos de la empresa (14.7% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: CDXSSe prevé que los ingresos de la empresa (14.7% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de CDXS se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Codexis Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 12%

Consensus EPS estimates fall by 15%

Price target decreased by 17% to US$6.20

Price target increased by 13% to US$8.40

Codexis, Inc. Reiterates Earnings Guidance for the Year 2023

Price target decreased by 7.1% to US$11.14

Recent updates

Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board

Consensus revenue estimates increase by 12%

High number of new directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board

Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director

Codexis, Inc. announced that it expects to receive $40 million in funding

New major risk - Share price stability

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS).

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 15%

Price target decreased by 17% to US$6.20

Price target increased by 13% to US$8.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Codexis, Inc. Reiterates Earnings Guidance for the Year 2023

Codexis, Inc. to Present Update on Eco Synthesis Platform At Tides Europe

Codexis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Codexis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

New minor risk - Share price stability

Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

Price target decreased by 7.1% to US$11.14

Codexis, Inc. Unveils Eco Synthesis Platform for Large-Scale RNAi Therapeutics Production at Tides USA

At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

Price target decreased by 10% to US$11.57

Codexis, Inc. Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Director & Strategic Advisor exercised options and sold US$152k worth of stock

Chief Operating Officer recently sold US$77k worth of stock

Consensus revenue estimates decrease by 16%

Price target decreased by 8.8% to US$13.00

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Director & Strategic Advisor notifies of intention to sell stock

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Codexis, Inc. Announces Cessation of Ross Taylor as Principal Financial and Accounting Officer

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Codexis, Inc. Announces Appointment of Sri Ryali as Chief Financial Officer

Codexis Appoints H. Stewart Parker to Board of Directors

Director & Strategic Advisor exercised options and sold US$132k worth of stock

Director & Strategic Advisor exercised options and sold US$157k worth of stock

Price target decreased to US$14.75

High number of new directors

Price target decreased to US$16.00

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. Reiterates Earnings Guidance for the Year 2022

High number of new directors

Codexis, Inc. Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel

Director & Strategic Advisor notifies of intention to sell stock

Codexis, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Director & Strategic Advisor exercised options and sold US$144k worth of stock

Codexis, Inc. Appoints Rahul Singhvi to Its Board of Directors

Codexis appoints Kevin Norrett as chief operating officer

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Director exercised options and sold US$495k worth of stock

Consensus forecasts updated

Codexis, Inc. Reiterates Earnings Guidance for 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead

Codexis, Inc. Announces CEO Changes, Effective August 9, 2022

Codexis gets new executive chief

Consensus EPS estimates fall by 26%